Trial Profile
A Phase II, Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Feb 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms HAWK
- Sponsors AstraZeneca
- 20 Feb 2023 Results of pooled analysis assessing the tumor mutational burden (TMB) and outcomes in the phase 2 HAWK/CONDOR (n=153) and phase 3 EAGLE (n=247) studies of durvalumab with or without tremelimumab in platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma, published in the Clinical Cancer Research.
- 11 Sep 2020 Status changed from active, no longer recruiting to completed.
- 27 Aug 2020 This trial has been completed in Hungary, according to European Clinical Trials Database record.